Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Edoxaban is a novel, orally available, highly specific direct inhibitor of factor Xa and is currently being developed for the treatment and prevention of venous thromboembolism and prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The objectives of the present analyses were to characterise edoxaban population pharmacokinetics (PPK) and identify potential intrinsic and extrinsic factors affecting variability in edoxaban exposure, determine if there are relationships between edoxaban pharmacokinetics or biomarkers and the risk of bleeding in patients with NVAF using an exposure-response model, and to use the PPK and exposure-response model to support dose selection for a phase III trial of edoxaban in patients with NVAF. PPK analysis of data from 1,281 edoxaban-dosed subjects with intrinsic factors such as renal impairment or NVAF and extrinsic factors such as concomitant medications revealed significant effects of renal impairment and concomitant strong P-glycoprotein (P-gp) inhibitors on the pharmacokinetics of edoxaban. Exposure-response analysis found that in patients with NVAF, the incidence of bleeding events increased significantly with increasing edoxaban exposure, with steady-state minimum concentration (Cmin,ss) showing the strongest association. Clinical trial simulations of bleeding incidence were used to select 30 mg and 60 mg once-daily edoxaban with 50% dose reductions for patients with moderate renal impairment or receiving concomitant strong P-gp inhibitors as the treatment regimens in the ENGAGE AF-TIMI 48 (NCT00781391) trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1160/TH11-08-0566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancer-associated thrombosis (CAT) is the second leading cause of death in cancer patients, significantly affecting quality of life, survival, and healthcare costs. This review summarizes key recommendations from the 2023 ESMO guidelines on CAT prevention and treatment, illustrated by a real-world case, and examines barriers to implementation. CAT risk is multifactorial, shaped by tumor-related factors (type, stage, time since diagnosis), treatment exposures (anticancer agents, surgery, central venous catheters), and comorbidities, captured by the "4TS" rule.
View Article and Find Full Text PDFVenous Thromboembolism Therapy with Edoxaban in Daily Care Patients: Results from the DRESDEN NOAC REGISTRY.
TH Open
July 2025
Division Hematology, Department of Medicine I, Thrombosis Research Unit, University Hospital "Carl Gustav Carus" Dresden, Dresden, Germany.
Direct oral anticoagulants such as edoxaban are standard of care in current treatment of venous thromboembolism (VTE). However, phase III trial data need confirmation in real-world settings. We extracted data from the prospective, noninterventional multiple-indication DRESDEN NOAC REGISTRY to evaluate outcome rates during VTE treatment with edoxaban.
View Article and Find Full Text PDFPopulation pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation.
J Thromb Haemost
July 2025
Gerontology and Geriatrics, Department of Public Health and Primary Care, Katholieke Universiteit Leuven-University of Leuven, Leuven, Belgium; Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium. Electronic address:
Background: Atrial fibrillation affects nearly half of geriatric inpatients, with edoxaban frequently used for stroke prevention. However, geriatric patients are underrepresented in drug trials with edoxaban. The limited data and high pharmacokinetic (PK) variability result in using this high-risk medication without a full understanding of its exposure in this population.
View Article and Find Full Text PDFRisk Assessment for Biopharmaceutics Classification System Class IV Molecule Containing Immediate Release Products: Use of In-Silico Prediction Tools and Physiologically Based Pharmacokinetic Modeling.
AAPS J
May 2025
Biopharmaceutics Group, Global Clinical Management, Integrated Product Development Organization (IPDO), Dr. Reddy's Laboratories Ltd, Bachupally, Medchal Malkajgiri District, Hyderabad, 500 090, Telangana, India.
Nitrosamines drug substance related impurities (NDSRI) are organic impurities, highly potent mutagenic substances that are classified as human carcinogens. Regulatory guidance's in this area provide procedures for control and risk mitigation of NDSRI's in drug products. While efforts are made to control the NDSRI's, cases where NDSRI's are observed post- pivotal bioequivalence studies may require additional bioequivalence studies, between pre- and post- change formulations.
View Article and Find Full Text PDFEffect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers.
Front Pharmacol
April 2025
Internal Medicine IX, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital, Heidelberg, Germany.
Purpose: Pregabalin, gabapentin, and carbamazepine, a potent inducer of cytochrome P450 (CYP) 3A4 and P-glycoprotein, are frequently used antiepileptic drugs that are often administered together with factor Xa inhibitors (FXaI). We aimed to investigate whether potentially clinically relevant drug-drug interactions occur with these combinations.
Methods: In an open-label fixed-sequence trial in 36 healthy volunteers, we evaluated the pharmacokinetics of 60 mg edoxaban and of a microdosed FXaI cocktail (25 µg apixaban, 50 µg edoxaban, and 25 µg rivaroxaban) before and during treatment with carbamazepine (12 evaluable volunteers, individually dosed to therapeutic concentrations), gabapentin (11 volunteers, titrated to 3 × 400 mg/d), and pregabalin (12 volunteers, titrated to 2 × 300 mg/d).